Playing 1/8
  • Synthesis of Diazepam Medicinal Chemistry Notes

    YouTube 08:22
  • The Professor on Viagra - Periodic Table of Videos

    YouTube 05:26
  • The Science of Caffeine: The World's Most Popular Drug

    YouTube 02:26
  • GSK – Our story

    YouTube 03:57
  • Postmenopausal Osteoporosis

    YouTube 02:56
  • Generic Viagra and Cialis custom compounded for you with Well Medical Arts in Seattle

    YouTube 01:20
  • How to Calculate Molar Mass (Molecular Weight)

    YouTube 03:51
  • xanthines pharmacology, theophylline, theobromine, theophylline mechanism of action

    YouTube 13:52

BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 family. PDE7 activity is encoded by two genes, PDE7A and PDE7B. BRL-50481 actually shows about an 80-fold preference for the PDE7A subtype, for which it was developed, over PDE7B. BRL-50481 has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.

Discover in context

This site is not available in the landscape mode.
Please rotate your phone or install our app.